Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy

J Clin Oncol. 2005 Apr 10;23(11):2574-6. doi: 10.1200/JCO.2005.81.908. Epub 2005 Mar 28.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects*
  • Camptothecin / analogs & derivatives*
  • Humans
  • Incidence
  • Irinotecan
  • Risk Factors
  • Stomach Neoplasms / complications
  • Stomach Neoplasms / drug therapy*
  • Thromboembolism / chemically induced*
  • Thromboembolism / epidemiology*
  • Thrombophilia / complications*
  • Thrombophilia / etiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Irinotecan
  • Camptothecin